Kalaris Therapeutics KLRS
NASDAQ KLRS
$2.90 +0.06 (+1.93%)
At close: Sep 29, 2026 · 4:00 PM EDT

Kalaris Therapeutics (KLRS) Research & Development (2019 - 2026)

Updated

Kalaris Therapeutics' Research & Development was $9.02 million in Q2 2026, up 6.8% from $8.44 million a year earlier and up 19.1% from the prior quarter.

Analysis

Kalaris Therapeutics (KLRS) Research & Development (2019 - 2026) Analysis & Trends

On a trailing twelve-month basis, Kalaris Therapeutics' Research & Development was $32.87 million through Jun 30, 2026, down 39.5% year-over-year; for FY2025, it was $30.75 million, down 31.7% from FY2024.

  • Research & Development shows a five-year compound annual growth rate of -9.1% (FY2020 to FY2025).
  • In earlier years, Research & Development was $45.04 million in FY2024 (-66.2%), $133.07 million in FY2023 (+11.9%), $118.87 million in FY2022 (-1.5%) and $120.74 million in FY2021 (+143.1%).
  • Quarterly Research & Development has moved between $1.96 million (Q1 2024) and $41.6 million (Q4 2021) over five years.
  • Compared with a year earlier, Research & Development has increased for three straight quarters, with growth averaging 41.4% over the last eight quarters.
  • The best year-over-year quarter for Research & Development over five years was Q1 2025 (growth of 207.5%); the worst was Q1 2024 (a decline of 93.6%).
  • Per Business Quant data, KLRS's Research & Development in the three quarters before Q2 2026 was $7.57 million (Q1 2026), $7.16 million (Q4 2025) and $9.13 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Kalaris Therapeutics 67.84 Mn 67.84 Mn - 9.02 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.02 Mn
Mar 31, 2026 7.57 Mn
Dec 31, 2025 7.16 Mn
Sep 30, 2025 9.13 Mn
Jun 30, 2025 8.44 Mn
Mar 31, 2025 6.03 Mn
Dec 31, 2024 3.85 Mn
Sep 30, 2024 36.02 Mn
Jun 30, 2024 3.21 Mn
Mar 31, 2024 1.96 Mn
Dec 31, 2023 33.37 Mn
Sep 30, 2023 34.16 Mn
Jun 30, 2023 34.82 Mn
Mar 31, 2023 30.72 Mn
Dec 31, 2022 28.42 Mn
Sep 30, 2022 30.00 Mn
Jun 30, 2022 31.38 Mn
Mar 31, 2022 29.07 Mn
Dec 31, 2021 41.60 Mn
Sep 30, 2021 33.06 Mn
API Access

Kalaris Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=KLRS&period=max&api_key=YOUR_API_KEY